{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-192923","form_type":"8-K/A","ticker":"LENZ","cik":"0001815776","company_name":"LENZ Therapeutics, Inc.","filed_at":"2022-07-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:57.170761+00:00","generated_at":"2026-06-24T16:06:56.766749+00:00","sec_items":["8.01","2.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Graphite Bio reports GPH102 preclinical HDR rates up to 40% in sickle cell HSPCs; IND planned mid-2024","bullets":["GPH102 gene replacement achieved homology directed repair (HDR) rates up to 40% in sickle cell HSPCs and restored adult hemoglobin (HbA) expression.","Company plans to submit an IND for GPH102 in beta-thalassemia by mid-2024, pending regulatory feedback.","An encore trial-in-progress poster for GPH101 Phase 1/2 CEDAR trial in sickle cell disease was also presented at ASGCT.","GPH102 uses UltraHDR platform to replace mutated beta-globin gene, targeting >300 mutations that cause beta-thalassemia."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-192923","json":"https://secwatch.observer/filing/0001193125-22-192923.json","markdown":"https://secwatch.observer/filing/0001193125-22-192923.md","text":"https://secwatch.observer/filing/0001193125-22-192923.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1815776/000119312522192923/0001193125-22-192923-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1815776/000119312522192923/d379068d8ka.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T16:06:56.766749+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}